Doctors injected patients’ own platelet-rich plasma into a worn spinal disc. Six months later, about eight in ten had much less back pain – though scans showed the disc itself had not rebuilt.
This article covers emerging musculoskeletal and regenerative-medicine research. It reflects what may be coming in the field, not the treatments ADX or its network physicians currently provide.
Why It Matters
The discs between the bones of your spine act like cushions. When one wears down, it can cause deep, lasting back pain that is hard to treat. One idea doctors have been testing is to take a small amount of a patient’s own blood, spin it down to concentrate the healing part, and inject that back into the damaged disc. This study followed patients who had that done and used detailed scans to look at what actually changed inside the spine. Most people felt much better. The surprising part is where the change showed up.
Summary
Researchers at the First Affiliated Hospital of Chongqing Medical University enrolled patients with discogenic low back pain between November 2023 and October 2024. Of 45 people screened, 29 completed the full protocol. Each received a single injection of leukocyte-poor platelet-rich plasma – 2 mL prepared from their own blood, with no anticoagulants or activating additives – placed directly into the center of one degenerated disc under X-ray guidance. Only single-level disease was treated, and only discs graded Pfirrmann III or IV, meaning moderately worn but not collapsed. Patients had to have a positive provocative test confirming the disc was the pain source before the injection went in; five people were excluded at that step. Pain, disability, and function were measured at baseline and at 1, 3, and 6 months, alongside quantitative MRI of both the disc and the vertebral bone above and below it.
The symptom results were consistent and substantial. Average pain on a 100-millimeter visual scale fell from 63.8 to 31.8. Oswestry Disability Index scores dropped from 42.0 percent to 20.9 percent, and Function Rating Index scores from 46.2 percent to 23.1 percent. All three changes were statistically significant. Using a strict combined standard – a 30 percent or greater improvement in both pain and disability – 48 percent of patients qualified as responders at one month, 62 percent at three months, and 79 percent at six months. Roughly the same proportion, 79 percent, reported being satisfied with the outcome. No adverse events, complications, or repeat operations occurred during follow-up.
The imaging is where the study gets interesting. If PRP were rebuilding the disc, the disc’s water content should rise on T2 mapping, its height should recover, and its degeneration grade should improve. None of that happened in any meaningful way. Whole-disc T2 values rose by about one millisecond over six months – statistically detectable but roughly a half-percent change, and not correlated with how patients felt. Disc height index was essentially unchanged (41.6 percent before, 41.4 percent after), and no disc improved its Pfirrmann grade. What did change was the bone on either side: the fat fraction in the vertebral marrow directly adjacent to the treated disc fell by about 6 to 7 percent, and that decline tracked with symptom improvement across all three questionnaires (correlation coefficients of roughly 0.46 to 0.56, all statistically significant).
The authors read this as evidence that the early benefit comes from a shift in the metabolic and inflammatory environment around the disc rather than from structural regeneration of the disc itself – at least within six months. That is a meaningful distinction for anyone weighing this treatment, and it is worth stating the limits plainly. This was a single-arm study with no sham or saline control, which the ethics committee declined to approve because a needle puncture alone can worsen a disc. The authors acknowledge that placebo effect may account for part of the improvement. The cohort was small, treated at one center, followed for only six months, and deliberately excluded the most severely degenerated discs. What the study does establish is a safety signal, a consistent early symptom response in carefully selected patients, and an objective imaging finding that gives future randomized trials something specific to test.
Source: Scientific Reports, Pan, Peng et al., 2026
Research compiled by ADX AI Agent, reviewed by Sean Gallivan